Report Highlights

Test Strip Packaging in the U.S.: Market Overview

The U.S. blood glucose test strip packaging market is valued at USD 412 million in 2024, a specialised niche within the diabetes diagnostics supply chain. Unlike global norms, where emerging markets drive volume through low-cost sachets and tenders, American demand is shaped by reimbursement rules and pharmacy benefit managers. Packaging specifications are set by strip manufacturers such as Abbott, Roche Diabetes Care and Ascensia Diabetes Care, not by end consumers.

Structurally, the market is concentrated at the converter tier. Five or six multinational packaging suppliers supply most barrier-foil and rigid tube components, while regional injection moulders serve private-label meter makers. Because strips are Class II in vitro diagnostic devices under 21 CFR 862.1345, packaging changes trigger stability revalidation, which lengthens supplier switching cycles and rewards incumbents with proven documentation.

Growth Drivers in U.S. Test Strip Packaging

Demand is anchored by the installed patient base. The CDC's National Diabetes Statistics Report counts 38.4 million Americans with diabetes, and Medicare Part B covers test strips for beneficiaries who use insulin or have documented hypoglycaemia risk. This recurring reimbursed consumption keeps strip volumes steady, so packaging converters ship against a predictable replenishment cycle that rarely contracts during economic slowdowns.

Two regulatory and channel shifts add further demand. FDA unique device identification rules under 21 CFR Part 801 require each strip package to carry a UDI and a matching GUDID record, prompting redesign of labels and print-ready substrates across the installed base. Meanwhile, CVS Caremark, Express Scripts and Optum Rx mail-order pharmacies ship 90-day supplies, which favours larger multi-count canisters with tamper-evident closures and drives multi-unit packaging volume.

Market Restraints and Entry Barriers

Medicare competitive bidding is the most severe pricing constraint. The CMS DMEPOS Competitive Bidding Program awards supply contracts at fixed national and regional prices, compressing supplier margins and pushing strip makers to demand lower packaging unit costs. Continuous glucose monitors from Dexcom and Abbott's FreeStyle Libre line are also taking insulin-user volume from strips, shrinking the addressable pool for packaging orders.

Entry barriers are primarily regulatory and contractual. Packaging changes that affect moisture or light stability require supplemental 510(k) documentation under 21 CFR 807.81, and new converters must pass supplier audits under the Quality Management System Regulation. Pharmacy benefit managers also control formulary placement, so packaging suppliers without a current contract with CVS Caremark or Express Scripts find their products excluded from patient-facing channels.

Market Opportunities in the U.S.

The clearest near-term opening is mono-material recyclable packaging. California's Plastic Pollution Prevention and Packaging Producer Responsibility Act (SB 54) and Maine's packaging stewardship fees push producers toward recyclable designs, and converters that redesign strip canisters in polypropylene can serve an addressable USD 85 million slice of 2024 canister spend. Brands that move early secure qualified designs before state recyclability thresholds tighten.

Private-label and retailer-branded strips offer a second entry route. Retailers such as Walmart, through its ReliOn range, and drugstore chains buy value-tier strips that require low-cost, high-volume packaging, creating an addressable USD 48 million segment of rigid vial and blister formats. This channel rewards converters with FDA-registered facilities and fast turnaround times.

Market at a Glance

Leading Market Participants

• Sonoco Products Company
• Amcor plc
• Berry Global
• AptarGroup
• Constantia Flexibles
• WestRock
• Gerresheimer
• Huhtamaki
• Pretium Packaging
• Tekni-Plex

Regulatory and Policy Environment

FDA oversight of strip packaging operates through the device's 510(k) clearance under 21 CFR 862.1345 and the unique device identification rule at 21 CFR Part 801. Manufacturers must submit a supplemental 510(k) when packaging materials change in ways that affect stability, and the Quality Management System Regulation at 21 CFR Part 820 takes full effect on 2 February 2026, aligning U.S. requirements with ISO 13485:2016. Converters serving strip makers must complete supplier controls and documentation before that date.

Packaging waste obligations are set by state legislatures rather than federal law. California's SB 54 establishes a producer responsibility organisation under CalRecycle, with regulations phasing in recyclability and source-reduction targets, while Maine's stewardship programme assigns fees to producers based on packaging weight and recyclability. Oregon's and Colorado's extended producer responsibility laws add further compliance obligations, and Section 301 tariffs raise costs on imported components from China used in rigid canisters.

Long-Term Outlook for U.S. Test Strip Packaging

By 2032, the U.S. market is forecast to reach USD 618 million, growing at a CAGR of 5.2% from the 2025 base year. Growth will concentrate in mail-order and specialty pharmacy channels, where multi-count canisters and tamper-evident closures dominate volume, while blister formats grow more slowly in retail.

The sharpest structural risk is continued substitution toward continuous glucose monitoring, which will cap strip consumption growth among insulin users. Converters that combine barrier-foil capability with mono-material recyclable designs will retain share, while suppliers dependent on single-format rigid vial production will face margin pressure as CGM adoption expands through 2032.